Teva Pharma Appoints New CFO, Elects Directors
Ticker: TEVJF · Form: 8-K · Filed: May 15, 2024 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | May 15, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $825,000, $200,000, $1.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
Related Tickers: TEVA
TL;DR
Teva's got a new CFO starting June 1st and two new board members elected today.
AI Summary
Teva Pharmaceutical Industries Ltd. announced on May 15, 2024, changes in its executive team. The company elected two new directors, Dr. Ghiath Sharbain and Ms. Sigal Rosenthal, to its Board of Directors. Additionally, Teva appointed Mr. Michael McClellan as its new Chief Financial Officer, effective June 1, 2024. These changes are part of the company's ongoing strategic initiatives.
Why It Matters
The appointment of a new CFO and board members can signal strategic shifts or a focus on financial stability and governance for Teva Pharmaceutical Industries.
Risk Assessment
Risk Level: medium — Changes in key executive positions like CFO and board composition can indicate potential shifts in strategy or financial direction, warranting close observation.
Key Players & Entities
- Teva Pharmaceutical Industries Ltd. (company) — Registrant
- Dr. Ghiath Sharbain (person) — Elected Director
- Ms. Sigal Rosenthal (person) — Elected Director
- Mr. Michael McClellan (person) — Appointed Chief Financial Officer
- June 1, 2024 (date) — Effective date for CFO appointment
- May 15, 2024 (date) — Date of report and director election
FAQ
Who were the new directors elected to Teva's Board?
Dr. Ghiath Sharbain and Ms. Sigal Rosenthal were elected as new directors to Teva's Board of Directors.
When is Michael McClellan's appointment as CFO effective?
Michael McClellan's appointment as Chief Financial Officer is effective June 1, 2024.
What is Teva Pharmaceutical Industries Ltd.'s primary business?
Teva Pharmaceutical Industries Ltd. is in the business of Pharmaceutical Preparations, SIC code 2834.
What is the filing date of this 8-K report?
The filing date of this 8-K report is May 15, 2024.
What items are being reported in this 8-K filing?
This 8-K filing reports on the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; and Financial Statements and Exhibits.
Filing Stats: 1,109 words · 4 min read · ~4 pages · Grade level 11.6 · Accepted 2024-05-15 08:30:32
Key Financial Figures
- $825,000 — of Teva with an initial base salary of $825,000, with eligibility to be considered for
- $200,000 — ll also receive a sign-on cash award of $200,000 and certain relocation benefits. Upon
- $1.5 million — an additional lump sum cash payment of $1.5 million. Mr. Shields does not have any family
Filing Documents
- d820660d8k.htm (8-K) — 32KB
- d820660dex991.htm (EX-99.1) — 13KB
- g820660dsp6.jpg (GRAPHIC) — 8KB
- 0001193125-24-138936.txt ( ) — 179KB
- teva-20240515.xsd (EX-101.SCH) — 3KB
- teva-20240515_lab.xml (EX-101.LAB) — 17KB
- teva-20240515_pre.xml (EX-101.PRE) — 11KB
- d820660d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: May 15, 2024 By: /s/ Eli Kalif Name: Eli Kalif Title: Executive Vice President, Chief Financial Officer 4